Transmitted antiretroviral-resistant HIV: A coming anarchy?

The Lancet Infectious Diseases

Volumn 11, Issue 5, 2011, Pages 336-337

  Milloy, M J ^a,b   Wood, Evan ^a,c  

^a ST PAUL S HOSPITAL   (Canada)

^b Centre for Health Services and Policy Research   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PRIORITY JOURNAL; VIRAL GENETICS; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; EUROPE; HIV INFECTIONS; HIV-1; HUMANS; MODELS, BIOLOGICAL; POPULATION SURVEILLANCE; WORLD HEALTH;

EID: 79955383016     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70068-8     Document Type: Letter

References (12)

1. Larder BA, Darby G, Richman DD HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989, 243:1731-1734.
2. Wainberg MA, Friedland G Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998, 279:1977-1983.
3. Smith RJ, Okano JT, Kahn JS, Bodine EN, Blower S Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco. Science 2010, 327:697-701.
4. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002, 288:181-188.
5. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002, 347:385-394.
6. Wittkop L, Günthard HF, de Wolf F, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011, published online Feb 28. 10.1016/S1473-3099(11)70032-9.
7. Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000, 283:2417-2426.
8. Oette M, Kaiser R, Daumer M, et al. Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr 2006, 41:573-581.
9. Gill VS, Lima VD, Zhang W, et al. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis 2010, 50:98-105.
10. Vercauteren J, Deforche K, Theys K, et al. The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal. Retrovirology 2008, 5:12.
11. von Wyl V, Yerly S, Burgisser P, et al. Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. Clin Infect Dis 2009, 48:979-987.
12. Hamers RL, Siwale M, Wallis CL, et al. HIV-1 drug resistance mutations are present in six percent of persons initiating antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr 2010, 55:95-101.